Eribulin in Metastatic TNBC: Real-World Data

Eribulin as Treatment for Metastatic Breast CancerПодробнее

Eribulin in Metastatic Breast CancerПодробнее

Eribulin’s Role in Triple-Negative Breast CancerПодробнее

Recent data on eribulin in metastatic breast cancer patients from SABCSПодробнее

A Study Investigating Pembrolizumab in Combination With Eribulin in TNBCПодробнее

Eribulin is effective in pretreated advanced breast cancer patientsПодробнее

Dr. Tolaney on Pembrolizumab Plus Eribulin in TNBCПодробнее

Treatment With Eribulin in Metastatic Breast CancerПодробнее

The role of chemotherapy in the treatment of metastatic breast cancer patientsПодробнее

Andrew Seidman, MD: Efficacy Data Supporting the Use of Eribulin MesylateПодробнее

Dr. Twelves Discusses Eribulin for the Treatment of Breast CancerПодробнее

Treatment With Eribulin Mesylate in Metastatic Breast CancerПодробнее

Atezolizumab, Cobimetinib, and Eribulin in Patients With Metastatic Inflammatory Breast CancerПодробнее

Patient Selection for Eribulin in Breast CancerПодробнее

Joyce O’Shaughnessy, MD: Candidacy for Eribulin TherapyПодробнее

Eribulin in Recurrent Metastatic ER+ Breast CancerПодробнее

Dr. O’Shaughnessy on Eribulin as First-Line Therapy for Metastatic HER2-Negative Breast CancerПодробнее

Joyce O’Shaughnessy, MD: Different Mechanisms of Action in EribulinПодробнее

Dr. McIntyre on a Phase II Study Analyzing First-Line Eribulin MesylateПодробнее